---
title: "Rhythm Pharmaceuticals CFO Hunter C. Smith Reports Sale of Common Shares"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275183344.md"
datetime: "2026-02-06T23:38:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275183344.md)
  - [en](https://longbridge.com/en/news/275183344.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275183344.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275183344.md) | [English](https://longbridge.com/en/news/275183344.md)


# Rhythm Pharmaceuticals CFO Hunter C. Smith Reports Sale of Common Shares

Hunter C. Smith, Chief Financial Officer of Rhythm Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-011651), on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Rhythm Pharma (RYTM.US)](https://longbridge.com/zh-HK/quote/RYTM.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)

## 相關資訊與研究

- [Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | INTS Stock News](https://longbridge.com/zh-HK/news/278874097.md)
- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/zh-HK/news/278565253.md)
- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/zh-HK/news/278880252.md)
- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/zh-HK/news/278542482.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-HK/news/278556054.md)